{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:28:12Z","timestamp":1790807292161,"version":"4.1.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"DOI":"10.1182\/blood.2024024877","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:31:09Z","timestamp":1718897469000},"page":"2561-2562","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Time for a new prognostic score in CLL?"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-1831","authenticated-orcid":false,"given":"Francesco","family":"Forconi","sequence":"first","affiliation":[{"name":"University of Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2024062015305656500_bib1","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","article-title":"Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2024062015305656500_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"2024062015305656500_bib3","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024062015305656500_bib4","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1182\/bloodadvances.2021006659","article-title":"High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL","volume":"6","author":"Chiodin","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024062015305656500_bib5","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2024062015305656500_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.2020010029","article-title":"Exploring the pathways to chronic lymphocytic leukemia","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024062015305656500_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers14030663","article-title":"Biological\u00a0and clinical insight from analysis of\u00a0the tumor B-cell receptor structure and\u00a0function in chronic lymphocytic leukemia","volume":"14","author":"Forconi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024062015305656500_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024062015305656500_bib9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024062015305656500_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/25\/2561\/2230218\/blood_bld-2024-024877-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/25\/2561\/2230218\/blood_bld-2024-024877-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:31:17Z","timestamp":1718897477000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/25\/2561\/516483\/Time-for-a-new-prognostic-score-in-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":10,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024877","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}